Processa Pharmaceuticals (PCSA) Net Income towards Common Stockholders (2012 - 2026)

Processa Pharmaceuticals (PCSA) has 15 years of Net Income towards Common Stockholders data on file, last reported at -$3.4 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 19.15% year-over-year to -$3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$14.1 million (down 17.97% YoY) and the FY2025 annual result came in at -$13.6 million, down 14.46% from the prior year.
• Net Income towards Common Stockholders retreated to -$3.4 million in Q1 2026, from -$3.4 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$2.1 million in Q3 2023 to a low of -$13.0 million in Q4 2022.
• A 5-year average of -$4.0 million and a median of -$3.4 million in 2025 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders slumped 308.7% — and 2023, when it jumped 81.52%.
• Tracing PCSA's Net Income towards Common Stockholders over 5 years: stood at -$13.0 million in 2022, then jumped by 81.52% to -$2.4 million in 2023, then fell by 13.46% to -$2.7 million in 2024, then declined by 23.1% to -$3.4 million in 2025, then dropped by 0.54% to -$3.4 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$3.4 million (Q1 2026), -$3.4 million (Q4 2025), and -$3.4 million (Q3 2025), per Business Quant data.